Literature DB >> 28053038

Large Soluble Oligomers of Amyloid β-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate.

Ting Yang1, Shaomin Li1, Huixin Xu1, Dominic M Walsh2, Dennis J Selkoe2.   

Abstract

Soluble oligomers of amyloid β-protein (oAβ) isolated from the brains of Alzheimer's disease (AD) patients have been shown experimentally (in the absence of amyloid plaques) to impair hippocampal synaptic plasticity, decrease synapses, induce tau hyperphosphorylation and neuritic dystrophy, activate microglial inflammation, and impair memory in normal adult rodents. Nevertheless, there has been controversy about what types of oligomers actually confer these AD-like phenotypes. Here, we show that the vast majority of soluble Aβ species obtained from brains of humans who died with confirmed AD elute at high molecular weight (HMW) on nondenaturing size-exclusion chromatography. These species have little or no cytotoxic activity in several bioassays. However, incubation of HMW oAβ in mildly alkaline buffer led to their quantitative dissociation into low molecular weight oligomers (∼8-70 kDa), and these were now far more bioactive: they impaired hippocampal LTP, decreased neuronal levels of β2-adrenergic receptors, and activated microglia in wt mice in vivo Thus, most soluble Aβ assemblies in AD cortex are large and inactive but under certain circumstances can dissociate into smaller, highly bioactive species. Insoluble amyloid plaques likely sequester soluble HMW oligomers, limiting their potential to dissociate. We conclude that conditions that destabilize HMW oligomers or retard the sequestration of their smaller, more bioactive components are important drivers of Aβ toxicity. Selectively targeting these small, cytotoxic forms should be therapeutically beneficial. SIGNIFICANCE STATEMENT: Oligomers of amyloid β-protein (oAβ) are tought to play an important role in Alzheimer's disease (AD), but there is confusion and controversy about what types and sizes of oligomers have disease-relevant activity. Using size-exclusion chromatography and three distinct measures of bioactivity, we show that the predominant forms of Aβ in aqueous extracts of AD brain are high molecular weight (HMW) and relatively inactive. Importantly, under certain conditions, the abundant HMW oAβ can dissociate into low molecular weight species, and these low molecular weight oligomers are significantly more bioactive on synapses and microglia than the HMW species from which they are derived. We conclude that conditions that destabilize HMW oAβ or retard the sequestration of smaller, more bioactive components are important drivers of Aβ toxicity.
Copyright © 2017 the authors 0270-6474/17/370152-12$15.00/0.

Entities:  

Keywords:  Alzheimer's; Aβ aggregation; long-term potentiation; microglia activation; size-exclusion chromatography; β2-adrenergic receptor

Mesh:

Substances:

Year:  2017        PMID: 28053038      PMCID: PMC5214627          DOI: 10.1523/JNEUROSCI.1698-16.2016

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  41 in total

1.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

Review 2.  Functional consequences of locus coeruleus degeneration in Alzheimer's disease.

Authors:  David Weinshenker
Journal:  Curr Alzheimer Res       Date:  2008-06       Impact factor: 3.498

3.  Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo.

Authors:  Igor Klyubin; Dominic M Walsh; Cynthia A Lemere; William K Cullen; Ganesh M Shankar; Vicki Betts; Edward T Spooner; Liying Jiang; Roger Anwyl; Dennis J Selkoe; Michael J Rowan
Journal:  Nat Med       Date:  2005-04-17       Impact factor: 53.440

4.  Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies.

Authors:  Patricia Szot; Sylvia S White; J Lynne Greenup; James B Leverenz; Elaine R Peskind; Murray A Raskind
Journal:  J Neurosci       Date:  2006-01-11       Impact factor: 6.167

Review 5.  A beta oligomers - a decade of discovery.

Authors:  Dominic M Walsh; Dennis J Selkoe
Journal:  J Neurochem       Date:  2007-02-05       Impact factor: 5.372

6.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

Review 7.  Noradrenergic mechanisms in neurodegenerative diseases: a theory.

Authors:  Marc R Marien; Francis C Colpaert; Alan C Rosenquist
Journal:  Brain Res Brain Res Rev       Date:  2004-04

8.  Alzheimer brain-derived amyloid β-protein impairs synaptic remodeling and memory consolidation.

Authors:  Gilyana G Borlikova; Margarita Trejo; Alexandra J Mably; Jessica M Mc Donald; Carlo Sala Frigerio; Ciaran M Regan; Keith J Murphy; Eliezer Masliah; Dominic M Walsh
Journal:  Neurobiol Aging       Date:  2012-11-22       Impact factor: 4.673

9.  Peripheral administration of a humanized anti-PrP antibody blocks Alzheimer's disease Aβ synaptotoxicity.

Authors:  Igor Klyubin; Andrew J Nicoll; Azadeh Khalili-Shirazi; Michael Farmer; Stephanie Canning; Alexandra Mably; Jacqueline Linehan; Alexander Brown; Madeleine Wakeling; Sebastian Brandner; Dominic M Walsh; Michael J Rowan; John Collinge
Journal:  J Neurosci       Date:  2014-04-30       Impact factor: 6.167

10.  mGlu5 receptors and cellular prion protein mediate amyloid-β-facilitated synaptic long-term depression in vivo.

Authors:  Neng-Wei Hu; Andrew J Nicoll; Dainan Zhang; Alexandra J Mably; Tiernan O'Malley; Silvia A Purro; Cassandra Terry; John Collinge; Dominic M Walsh; Michael J Rowan
Journal:  Nat Commun       Date:  2014-03-04       Impact factor: 14.919

View more
  107 in total

Review 1.  The vexing complexity of the amyloidogenic pathway.

Authors:  Manuel A Castro; Arina Hadziselimovic; Charles R Sanders
Journal:  Protein Sci       Date:  2019-04-11       Impact factor: 6.725

2.  BACE inhibition-dependent repair of Alzheimer's pathophysiology.

Authors:  Aylin D Keskin; Maja Kekuš; Helmuth Adelsberger; Ulf Neumann; Derya R Shimshek; Beomjong Song; Benedikt Zott; Tingying Peng; Hans Förstl; Matthias Staufenbiel; Israel Nelken; Bert Sakmann; Arthur Konnerth; Marc Aurel Busche
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

Review 3.  Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease.

Authors:  Ralph A Nixon
Journal:  FASEB J       Date:  2017-07       Impact factor: 5.191

4.  Diet-induced insulin resistance elevates hippocampal glutamate as well as VGLUT1 and GFAP expression in AβPP/PS1 mice.

Authors:  Erin R Hascup; Sarah O Broderick; Mary K Russell; Yimin Fang; Andrzej Bartke; Heather A Boger; Kevin N Hascup
Journal:  J Neurochem       Date:  2019-01-03       Impact factor: 5.372

Review 5.  Neuronal Cell Death.

Authors:  Michael Fricker; Aviva M Tolkovsky; Vilmante Borutaite; Michael Coleman; Guy C Brown
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

6.  Identification of neurotoxic cross-linked amyloid-β dimers in the Alzheimer's brain.

Authors:  Gunnar Brinkmalm; Wei Hong; Zemin Wang; Wen Liu; Tiernan T O'Malley; Xin Sun; Matthew P Frosch; Dennis J Selkoe; Erik Portelius; Henrik Zetterberg; Kaj Blennow; Dominic M Walsh
Journal:  Brain       Date:  2019-05-01       Impact factor: 13.501

Review 7.  What Happens with the Circuit in Alzheimer's Disease in Mice and Humans?

Authors:  Benedikt Zott; Marc Aurel Busche; Reisa A Sperling; Arthur Konnerth
Journal:  Annu Rev Neurosci       Date:  2018-07-08       Impact factor: 12.449

8.  A mechanistic model to predict effects of cathepsin B and cystatin C on β-amyloid aggregation and degradation.

Authors:  Tyler J Perlenfein; Regina M Murphy
Journal:  J Biol Chem       Date:  2017-10-18       Impact factor: 5.157

Review 9.  Microglia in Alzheimer's disease.

Authors:  Heela Sarlus; Michael T Heneka
Journal:  J Clin Invest       Date:  2017-09-01       Impact factor: 14.808

10.  Physiological Aβ Concentrations Produce a More Biomimetic Representation of the Alzheimer's Disease Phenotype in iPSC Derived Human Neurons.

Authors:  Bonnie J Berry; Alec S T Smith; Christopher J Long; Candace C Martin; James J Hickman
Journal:  ACS Chem Neurosci       Date:  2018-05-22       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.